Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who are willing and able to sign a written consent form
• People whose general health and ability to carry out daily activities meets a certain standard (rated on a medical scale; a lower level of fitness may still be considered with approval from the trial's medical monitor — confirm with trial site)
• People with a confirmed diagnosis of a specific type of aggressive blood cancer called Diffuse Large B-Cell Lymphoma (DLBCL), including several subtypes, based on a 2016 international classification system — including cases where DLBCL developed from a slower-growing lymphoma (with one specific exception; confirm with trial site)
• People whose cancer has continued to grow or spread after at least two previous courses of treatment, and whose prior treatment included specific chemotherapy and antibody drugs (anthracycline and rituximab, or a similar CD20-targeting drug)
• People for whom a stem cell transplant or a specific type of immune cell therapy (CAR-T) has either not worked or is not a suitable option
• People who have at least one measurable area of disease that can be tracked using standard imaging criteria
• People who are willing to provide tumour tissue samples before and during treatment
• People who meet specific blood and organ function test results as defined in the trial protocol
• People with a life expectancy of more than 3 months

Who may not be able to join:

• People whose lymphoma has spread to the brain or spinal cord, or the fluid surrounding them
• People who have received chemotherapy, immunotherapy, major surgery, or another experimental treatment within 28 days before the trial starts (or within a shorter timeframe depending on the specific treatment — confirm with trial site)
• People who have had radiation therapy within 14 days before the trial starts
• People who have had a stem cell transplant within the last 100 days
• People who have received CAR-T cell therapy within the last 28 days
• People with a diagnosed immune deficiency condition, or a history of an active autoimmune disease that required ongoing medical treatment in the past 2 years
• People with serious active infections that are not currently under control (note: certain managed infections such as Hepatitis B, Hepatitis C, or HIV may still be considered — confirm with trial site)
• People with a history of another cancer, unless that cancer has been in remission for 2 or more years before the trial begins

Important: Always verify eligibility with the trial site directly before applying.